HomeCompareBLCM vs MRK

BLCM vs MRK: Dividend Comparison 2026

BLCM yields 2675.59% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLCM wins by $153201888663.82M in total portfolio value
10 years
BLCM
BLCM
● Live price
2675.59%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$153201888663.88M
Annual income
$142,709,556,416,008,380.00
Full BLCM calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BLCM vs MRK

📍 BLCM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLCMMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLCM + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLCM pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLCM
Annual income on $10K today (after 15% tax)
$227,424.75/yr
After 10yr DRIP, annual income (after tax)
$121,303,122,953,607,120.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BLCM beats the other by $121,303,122,953,598,780.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLCM + MRK for your $10,000?

BLCM: 50%MRK: 50%
100% MRK50/50100% BLCM
Portfolio after 10yr
$76600944331.97M
Annual income
$71,354,778,208,009,090.00/yr
Blended yield
93.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BLCM
Analyst Ratings
9
Buy
Consensus: Buy
Altman Z
-129.7
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLCM buys
0
MRK buys
0
No recent congressional trades found for BLCM or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLCMMRK
Forward yield2675.59%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$153201888663.88M$56.8K
Annual income after 10y$142,709,556,416,008,380.00$9,798.13
Total dividends collected$152471773366.59M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: BLCM vs MRK ($10,000, DRIP)

YearBLCM PortfolioBLCM Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$278,259$267,558.53$11,206$366.19+$267.1KBLCM
2$7,255,722$6,957,985.27$12,650$502.35+$7.24MBLCM
3$177,326,927$169,563,304.48$14,407$694.19+$177.31MBLCM
4$4,062,692,158$3,872,952,346.55$16,585$967.82+$4062.68MBLCM
5$87,274,395,543$82,927,314,933.13$19,342$1,363.89+$87274.38MBLCM
6$1,758,278,261,281$1,664,894,658,050.44$22,913$1,947.19+$1758278.24MBLCM
7$33,228,917,517,770$31,347,559,778,199.17$27,662$2,823.89+$33228917.49MBLCM
8$589,221,826,220,148$553,666,884,476,134.20$34,159$4,173.35+$589221826.19MBLCM
9$9,805,917,988,665,990$9,175,450,634,610,432.00$43,337$6,308.80+$9805917988.62MBLCM
10$153,201,888,663,881,000$142,709,556,416,008,380.00$56,776$9,798.13+$153201888663.82MBLCM

BLCM vs MRK: Complete Analysis 2026

BLCMStock

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Full BLCM Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BLCM vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLCM vs SCHDBLCM vs JEPIBLCM vs OBLCM vs KOBLCM vs MAINBLCM vs JNJBLCM vs ABBVBLCM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.